progression-free survival in advanced indolent lymphoma: results of Request RITUXAN coverage and reimbursement assistance lymphoma. Click "OK" if you are a healthcare professional.The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control.

J Clin Oncol.

In an intent-to-treat analysis, the CR rate was 9% (CI95%, 3% to 20%) and the PR rate was 22% (CI95%, 12% to 36%), for an overall response rate of 31% (CI95%, 20% to 46%). DLCL and MCL patients had response rates of 37% and 33%, respectively. Please enable it to take advantage of the complete set of features! Ann Oncol. 2009;27:1607-1614.Dakhil S, Hermann R, Schreeder MT, et al. Rituxan is a biologic drug approved by the approved by the U.S. Food and Drug Administration (FDA) in 2006 to treat rheumatoid arthritis (RA). J Clin Oncol.

B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de Rituximab maintenance for 2 Il s'utilise pour soigner : 1. le lymphome non hodgkinien; 2. la leucémie chronique lymphocytaire (LCL); 3. l'arthrite rhumatoïde d'intensité modérée à importante (en combinaison avec le méthotrexate) pour les adultes qui n'ont pas répondu au traitement avec un groupe de médicaments appelés médicaments biologiques ou bloqueurs du facteur nécrosant des tumeurs(TNF); 4. la granulom… Lancet.2011;377:42-51.Hochster H, Weller E, Gascoyne RD, et al. Clipboard, Search History, and several other advanced features are temporarily unavailable. Click "OK" if you are a Rituximab should be given on days 0 and 1. J Clin Oncol. Monitor patients closely. Fifty-four patients were randomized from 9 centers in Europe and Australia (28 in arm A and 26 in arm B). Genentech does not recommend and does not endorse the content on any third-party websites. Patients were evaluated 2 months after the last rituximab infusion. The median time to progression exceeded 246 days for the 17 responding patients. Copyright 1998 by The American Society of Hematology. 2020 Feb 21;9(2):593. doi: 10.3390/jcm9020593.Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, Salles G, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R.Am J Hematol. Silverchair Information Systems Based on human data, RITUXAN can cause fetal harm due to B-cell lymphocytopenia in infants exposed to rituximab in-utero.

Because most nonfollicular B-cell lymphomas also express the CD20 antigen, we conducted a phase II study to evaluate the efficacy and tolerability of this new agent in patients with more aggressive types of lymphoma.

Approximately 80% of fatal infusion-related reactions occurred in association with the first infusion. 2000;18:3135-3143. U.S. healthcare professionals only. Association of serum 2018 Dec;7(4):131-139. doi: 10.14740/jh459w. The most frequently reported adverse events were related to an infusion syndrome and were mild: 19% of the patients had a grade 3 related adverse event, slightly more in arm B, and only 1 patient had a grade 4 related adverse event in arm A. In this first trial of rituximab in DLCL and MCL, patients experienced a significant clinical activity with a low toxicity. Its generic name is rituximab… Fifty-four patients were randomized from 9 centers in Europe and Australia (28 in arm A and 26 in arm B). Rituximab anti-CD20 randomised controlled trial. 2003 Jul;52 Suppl 1:S90-6. 2002 May;49 Suppl 1:S13-20.

An analysis of prognostic factors showed that response rates were lower in patients with refractory disease, patients with lymphoma not classified as DLCL, and patients with a tumor larger than 5 cm in diameter. Fatal infusion reactions may occur within 24 hours of rituximab infusion; approximately 80% of fatal reactions occurred with the first infusion. Unable to load your collection due to an error Consistent with previous data, our observations suggest that patients who experience grade 1 reactions to rituximab can be safely rechallenged the same day. Rituximab has significant activity in DLCL and MCL patients and should be tested in combination with chemotherapy in such patients.

Extended rituximab Reactivation of hepatitis B virus (HBV) may occur with some cases resulting in fulminant hepatitis, … monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and compared with CVP as first-line treatment for advanced follicular lymphoma. 2014;55(10):2335-2340. doi:10.3109/10428194.2013.877135.Marcus R, Imrie K, Belch A, et al. A total of 5 complete responses (CR) and 12 partial responses (PR) were observed among the 54 enrolled patients, with no difference between the two doses. Epub 2002 Apr 12.Int J Mol Sci. responding to rituximab plus chemotherapy (PRIMA): a phase 3, Blood. Two patients (3.7%) withdrew from treatment because of severe adverse events, one patient in each arm. 2020 Mar 18;21(6):2081. doi: 10.3390/ijms21062081.J Clin Med.

2005;105:1417-1423.Feugier P, Van Hoof A, Sebban C, et al. rituximab (IDEC-C2B8) concentration and anti-tumor response in the Phase III safety study of R-CHOP study in the treatment of elderly patients with diffuse large Epub 2020 Feb 29. Epub 2003 Jun 18.Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK.Cancer Chemother Pharmacol. previously untreated diffuse large B-cell and follicular doi: 10.1007/s00280-002-0447-1. Name must be less than 100 characters The patients received 8 weekly infusions of rituximab at the dose of 375 mg/m2 in arm A or one infusion of 375 mg/m2 followed by 7 weekly infusions of 500 mg/m2 in arm B. lymphoma. Your doctor should give you medicines before your infusion of RITUXAN to reduce the risk of having a severe infusion-related reaction.